Catégorie : Essais Cliniques

Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5- HT2A receptor, Katrin H. Preller, Franz X. Vollenweider et al., 2018

Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5- HT2A receptor Katrin H. Preller, Joshua B. Burt, Jie Lisa Ji, Charles Schleifer, Brendan D. Adkinson, Philipp Stampfli, Erich Seifritz, Grega Repovs, John H. Krystal, John D. Murray, Franz X. Vollenweider, Alan Anticevic eLife, 2018, 7, e35082. DOI: https://doi.org/10.7554/eLife.35082.001 Abstract Background : Lysergic acid diethylamide (LSD) has agonist activity at various serotonin (5-HT) and dopamine receptors. Despite the therapeutic and scientific interest in LSD, specific receptor  contributions to its neurobiological effects remain unknown. Methods : We therefore conducted a double-blind, randomized, counterbalanced, cross-over study (ClinicalTrials.gov, NCT02451072) during which [...]

Lire la suite

Introduction to Recent Advances in Cannabinoid Research, Robert B. Laprairie and Will Costain, 2016

Introduction to Recent Advances in Cannabinoid Research Robert B. Laprairie and Will Costain © 2016 The Author(s). Licensee InTechOpen. This chapter is distributed under the terms of the Creative Commons; Attribution License (http://creativecommons.org/licenses/by/3.0), Abstract On October 17, 2018, Canada became the first G20 nation to legalize the use of Cannabis sativa for both medicinal and recreational purposes. This change in legislation and end of prohibition are indicative of a larger global movement to understand Cannabis—and the bioactive chemicals present within Cannabis known as the cannabinoids—for its potential biomedical uses, harms, and economic values. Currently, interest in Cannabis and cannabinoid research is surging as the many [...]

Lire la suite

Hepatotoxicity of a Cannabidiol-Rich Cannabis Extract in the Mouse Model, Laura E. Ewing et al., 2019

Hepatotoxicity of a Cannabidiol-Rich Cannabis Extract in the Mouse Model Laura E. Ewing, Charles M. Skinner, Charles M. Quick, Stefanie Kennon-McGill, Mitchell R. McGill, Larry A. Walker, Mahmoud A. ElSohly, Bill J. Gurley and Igor Koturbash Molecules, 2019, 24, 1694 doi : 10.3390/molecules24091694 Abstract : The goal of this study was to investigate Cannabidiol (CBD) hepatotoxicity in 8-week-old male B6C3F1 mice. Animals were gavaged with either 0, 246, 738, or 2460 mg/kg of CBD (acute toxicity, 24 h) or with daily doses of 0, 61.5, 184.5, or 615 mg/kg for 10 days (sub-acute toxicity). These doses were the allometrically scaled mouse equivalent doses (MED) [...]

Lire la suite

Study will test pot’s effects on infants’ brain development, Brian Donohue, UW Medicine School of Medecine, 2019

May 10, 2019 Study will test pot’s effects on infants’ brain development Researchers seek to isolate cannabis from concurrent use of alcohol, tobacco, and illicit drugs. Media Contact: Brian Donohue - 206.543.7856, bdonohue@uw.edu Kleinhans Lab MRI scans of infants’ brains are part of the evaluation to discern effects of prenatal marijuana exposure. UW Medicine researchers are recruiting pregnant women to study whether prenatal marijuana use – in the absence of alcohol, tobacco, and any illicit drug consumption – affects their infants’ brain development, cognitive and motor development, medical health, and social behavior. The “Moms + Marijuana” study is co-led by Drs. Natalia Kleinhans and Stephen Dager, radiologists at [...]

Lire la suite

Cannabis For Cancer-Related Symptoms (CAFCARS), ClinicalTrials.gov Identifier : NCT03948074, mai 2019

Cannabis For Cancer-Related Symptoms (CAFCARS) https://clinicaltrials.gov/ct2/show/NCT03948074?recrs=abdf&cond=cannabis&draw=2&rank=98 ClinicalTrials.gov Identifier: NCT03948074 Recruitment Status : Not yet recruiting First Posted : May 13, 2019 Last Update Posted : May 13, 2019 See Contacts and Locations Sponsor: Pippa Hawley Information provided by (Responsible Party): Pippa Hawley, British Columbia Cancer Agency Study Description Brief Summary: Clinical evidence is urgently needed to be able to advise patients on which cannabis-based products to take, or to avoid, in managing cancer-related symptoms. This trial was therefore designed to determine which cannabis extract combination (High THC-Low CBD, Low THC-High CBD, or Equal amounts of THC and CBD) is most effective at treating cancer related symptoms for each [...]

Lire la suite

Measuring Disturbance of the Endocannabinoid System in Psychosis. A Systematic Review and Meta-analysis, Amadeo Minichino et al., 2019

Measuring Disturbance of the Endocannabinoid System in Psychosis. A Systematic Review and Meta-analysis Amedeo Minichino, MD1; Morwenna Senior, MD1; Natascia Brondino, PhD2; et al Sam H Zhang, BA1; Beata R Godwlewska, PhD1; Philip W.J Burnet, PhD1; Andrea Cipriani, PhD1,3; Belinda R. Lennox, DM1 JAMA Psychiatry, Published online June 5, 2019. doi:10.1001/jamapsychiatry.2019.0970 Editorial : Pathophysiology of Endocannabinoid Signaling in Schizophrenia David W. Volk, MD, PhD; David A. Lewis, MD   Question  Is the endocannabinoid system abnormal in people with psychosis? Findings  In this systematic review and meta-analysis of 18 studies, a higher tone of the endocannabinoid system was observed in people with psychosis, a finding that was consistent across all stages of illness and independent of antipsychotic treatment and current cannabis use. This increased tone was [...]

Lire la suite

Ketamine and Other NMDA Antagonists : Early Clinical Trials and Possible Mechanisms in Depression, D. Jeffrey Newport et al., 2015

Ketamine and Other NMDA Antagonists : Early Clinical Trials and Possible Mechanisms in Depression D. Jeffrey Newport, M.D., M.S., M.Div., Linda L. Carpenter, M.D., William M. McDonald, M.D., James B. Potash, M.D., M.P.H., Mauricio Tohen, M.D., Dr.P.H., M.B.A., Charles B. Nemeroff, M.D., Ph.D., The APA Council of Research Task Force on Novel Biomarkers and Treatments American Journal of Psychiatry, 2015, 172, 950–966 doi: 10.1176/appi.ajp.2015.15040465     Objective : The authors conducted a systematic review and meta-analysis of ketamine and other N-methyl-D-aspartate (NMDA) receptor antagonists in the treatment of major depression. Method : Searches of MEDLINE, PsycINFO, and other databases were conducted for placebo-controlled, double-blind, randomized clinical trials [...]

Lire la suite

Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression. A Randomized Clinical Trial, Ella J. Daly et al., 2019

Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression. A Randomized Clinical Trial Ella J. Daly, MD; Madhukar H. Trivedi, MD; Adam Janik, MD; Honglan Li, MD, PhD; Yun Zhang, PhD; Xiang Li, PhD; Rosanne Lane, MAS; Pilar Lim, PhD; Anna R. Duca, BSN; David Hough, MD; Michael E. Thase, MD; John Zajecka, MD; Andrew Winokur,MD, PhD; Ilona Divacka, MBA, MD; Andrea Fagiolini, MD; Wiesław J. Cubała, MD, PhD; István Bitter,MD, PhD; Pierre Blier,MD, PhD; Richard C. Shelton, MD; Patricio Molero,MD, PhD; Husseini Manji, MD;Wayne C. Drevets, MD; Jaskaran B. Singh, MD JAMA Psychiatry, [...]

Lire la suite

Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder : A Double-Blind Randomized Placebo-Controlled Trial, Yasmin L. Hurd, Sharron Spriggs, et al., 2019

Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder : A Double-Blind Randomized Placebo-Controlled Trial Yasmin L. Hurd, Ph.D., Sharron Spriggs, M.A., Julia Alishayev, R.P.A., Gary Winkel, Ph.D., Kristina Gurgov, R.P.A., Chris Kudrich, D.H.Sc., Anna M. Oprescu, M.P.H., Edwin Salsitz, M.D. AJP in Advance, 2019, 1-12. doi: 10.1176/appi.ajp.2019.18101191   Objective : Despite the staggering consequences of the opioid epidemic, limited nonopioid medication options have been developed to treat this medical and public health crisis. This study investigated the potential of cannabidiol (CBD), a nonintoxicating phytocannabinoid, to reduce cue-induced craving and anxiety, two critical features of addiction that often [...]

Lire la suite

Cannabidiol regulation of emotion and emotional memory processing : relevance for treating anxiety-related and substance abuse disorders, Jonathan L.C. Lee et al., 2017

Cannabidiol regulation of emotion and emotional memory processing : relevance for treating anxiety-related and substance abuse disorders Jonathan L.C. Lee, Leandro J. Bertoglio, Francisco S. Guimarães and Carl W. Stevenson British Journal of Pharmacology, 2017, 174, 3242–3256 DOI : 10.1111/bph.13724 Abstract Learning to associate cues or contexts with potential threats or rewards is adaptive and enhances survival. Both aversive and appetitive memories are therefore powerful drivers of behaviour, but the inappropriate expression of conditioned responding to fear- and drug-related stimuli can develop into anxiety-related and substance abuse disorders respectively. These disorders are associated with abnormally persistent emotionalmemories and inadequate treatment, often leading to symptom relapse. [...]

Lire la suite